US 9,809,816 B2
Treatment of NANOG related diseases by inhibition of natural antisense transcript to NANOG
Joseph Collard, Delray Beach, FL (US); and Olga Khorkova Sherman, Tequesta, FL (US)
Assigned to CuRNA, Inc., Miami, FL (US)
Filed by CuRNA, Inc., Miami, FL (US)
Filed on Feb. 5, 2015, as Appl. No. 14/615,040.
Application 14/615,040 is a division of application No. 13/989,124, granted, now 8,987,225, previously published as PCT/US2011/061140, filed on Nov. 17, 2011.
Claims priority of provisional application 61/416,341, filed on Nov. 23, 2010.
Prior Publication US 2015/0166994 A1, Jun. 18, 2015
This patent is subject to a terminal disclaimer.
Int. Cl. C07H 21/04 (2006.01); C12N 15/113 (2010.01); A61K 31/713 (2006.01)
CPC C12N 15/113 (2013.01) [A61K 31/713 (2013.01); C07H 21/04 (2013.01); C12N 2310/11 (2013.01); C12N 2310/113 (2013.01); C12N 2310/14 (2013.01); C12N 2310/314 (2013.01); C12N 2310/315 (2013.01); Y10T 436/143333 (2015.01)] 16 Claims
1. A pharmaceutical composition comprising a synthetic, modified oligonucleotide of 10 to 30 nucleotides in length comprising at least one modification wherein the at least one modification is selected from: at least one modified sugar moiety; at least one modified internucleotide linkage; at least one modified nucleotide, and combinations thereof; wherein said oligonucleotide is a single-stranded antisense compound which specifically hybridizes to a target region of a natural antisense polynucleotide of a NANOG gene having SEQ ID NO: 2 and is at least 90% complementary to said natural antisense polynucleotide and upregulates the function and/or expression of an NANOG gene in vivo or in vitro as compared to a normal control and a pharmaceutically acceptable excipient.